Transparency Market Research is Published
new Market Report "Endocrine Testing Market (E2, FSH, hCG, LH, DHEAS,
Progesterone, Testosterone, TSH, Prolactin, Cortisol, Insulin Tests and
Others)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast,
2013 - 2019," the global endocrine testing market was valued
at USD1.53billion in 2012 and is estimated to reach a market
worth USD2.03 billion in 2019 growing at a CAGR of 4.3% from 2013 to
2019.
Browse Endocrine Testing Market
Report with Full TOC at http://www.transparencymarketresearch.com/endocrine-testing-market.html
Endocrine system refers to the collection of endocrine glands (ductless
glands) and secretory organs that release hormones directly into the blood
stream. Endocrine system is instrumental in regulating certain body mechanisms
such as metabolism, growth and sexual development and emotions. Also, it enables
the body to cope up with different events such as cellular mechanisms and
stress by acting in co-ordination with the nervous system. Hormones refer to
the body's chemical messengers and render information and instruction transfer
from one set of cells to another. Hormones can act only on those cells that are
genetically programmed to receive and respond to the information or
instructions released by hormones. There are lot of factors that influence the
hormone levels including changes in body fluids and minerals in blood along
with stress and infection.
Several endocrine tests are performed to assess varying levels of
hormones in the body. This results in the determination of hypersecretion
(excess) or hyposecretion (less) that consequently helps in early diagnosis and
treatment of several endocrine disorders (such as sexual dysfunction, diabetes
and others). Consistent rise in diabetic, obese and infertile patient
population across the globe has broadened the scope for growth and acceptance
of various endocrine test kits. In addition, introduction of technologically
advanced diagnostic platforms coupled with growing healthcare awareness and
surge in preference for quick and easy operating test platforms have further
augmented the growth prospects for endocrine test kits or methodologies. On the
contrary, high development costs and less flexible reimbursement policies are
some of the factors that may hamper the growth of global endocrine testing
market.
Endocrine tests are instrumental in monitoring the normal and abnormal
levels of hormones secreted in the body. The market for insulin tests is
estimated to record highest growth rate during the forecast period majorly due
to increasing incidence of the diabetes worldwide coupled with technological
advances and increasing healthcare awareness across the globe. As per
International Diabetes Federation (IDF), in the year 2013, around 382 million
people suffered from diabetes and are anticipated to rise to 592 million by
2035. Also, 80% of the diabetic population lives in low and middle income
nations. Thyroid stimulating hormone test constituted the largest market
segment owing to increasing thyroid dysfunction cases and pose high risk for
acquiring cardiovascular disorders. The increased acceptance of endocrine test
kits is attributed to increasing incidence of obesity, unhealthy food habits,
physical inactivity and consistent technological advances. Follicle stimulating
hormone test followed by human chorionic Gonadotropin test occupied third and
fourth position in the market by 2019. Hence, all these factors mentioned above
influence the growth and acceptance of several test kits.
Among the diagnostic technology market the tandem mass spectrometry
segment is estimated to record highest growth rate due to high specificity and
accuracy rendered by this platform in determination of hormone levels.
Immunoassays and sensor technologies are expected to be the other fastest
growing diagnostic technology segments during the forecast period owing to
their increased use in several endocrine testing methodologies. However, high
cost involved in the research and development along with subsequent
commercialization of the same results in the high costs of the tests thereby
hampering the growth of the market.
While, the ambulatory care centers of the total market, by end users
segment is expected to be the fastest growing segment during the forecast
period due to quick service offerings and costs reduction due to less hospital
stay and gain competitive edge over the other end users. In addition, home
based tests and commercial laboratories are also expected to grow considerably
as compared to others (hospitals and physician offices).
At the regional level, Europe was the largest market in
2012for endocrine testing market followed by North America. The
growth has been attributed to the presence of sophisticated laboratories along
with increased participation of the respective governments in these
regions. Asia-Pacific region represents the fastest growing region
during the forecast period from 2013 to 2019.This is majorly due to huge
untapped patient population, increasing healthcare awareness and healthcare
spending and presence of large number of undiagnosed and untreated patients in
low and middle income nations. In addition, rise in disposable incomes and
increased investments of many key players in these emerging economies will
further boost the growth and development in this region. For instance, Abbott
Laboratories has been investing heavily in the emerging economies such
as India and China to enhance their revenues to 50% by
2015. The company has opened around six manufacturing and R&D facilities
in Asia-Pacific region. This substantiates the lucrative business
opportunities in these regions and enables the companies to introduce and
commercialize quality endocrine tests thereby enhancing the strength of the
market players.
The endocrine testing market is characterized by the presence of
well-established as well as new players solely operating in this market. The
major companies competing in this market are Agilent
Technologies, F.Hoffmann La-Roche, Ltd., Abbott Laboratories and Siemens
Healthcare and DiaSorin S.p.A.
The Global endocrine testing market is segmented as follows:
Endocrine
TestingMarket, by Test
- · Estradiol (E2) Test
- · Follicle Stimulating Hormone (FSH) Test
- · Human Chorionic Gonadotropin (hCG) Test
- · Luteinizing Hormone (LH) Test
- · Dehydroepiandrosterone sulfate (DHEAS) Test
- · Progesterone Test
- · Testosterone Test
- · Thyroid Stimulating Hormone (TSH) Test
- · Prolactin Test
- · Cortisol Test
- · Insulin Test
- · Others (Gastrin, Thymosin, Secretin, etc.)
- · Endocrine Testing Market, by Diagnostic Technologies
- · Tandem Mass Spectrometry
- · Immunoassay Technologies
- · Monoclonal and Polyclonal Antibody Technologies
- · Sensor Technologies
- · Clinical Chemistry Technologies
- · Others
Endocrine
Testing Market, by End Users
- · Hospitals
- · Commercial Laboratories
- · Ambulatory Care Centers
- · Home Based Tests
- · Physician Offices
Endocrine
Testing Market, by Geography
- · North America
- · Europe
- · Asia-Pacific
- · Rest of the World (RoW)
About Us:
Transparency Market Research is a market intelligence company
providing global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers.
We are privileged with highly experienced team of Analysts,
Researchers and Consultants, who use proprietary data sources and various tools
and techniques to gather, and analyze information. Our business offerings
represent the latest and the most reliable information indispensable for
businesses to sustain a competitive edge.
Contact:
Transparency Market Research
90 State Street,
Suite 700, Albany,NY – 12207,
United States
Tel: +1-518-618-1030
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
